Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
Gain expert insight on managing NTRK- and RET-altered malignancies and optimal methods for detecting gene fusions, in this webcast from Clinical Care Options (CCO)
Dr Evan J. Lipson shares expert insights on the safety and efficacy of anti-LAG-3 immunotherapies in this webcast from Clinical Care Options (CCO)
Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered malignancies.
Downloadable PDF resource on LAG-3, safety and efficacy of approved anti-LAG-3 agent relatlimab, and clinical trial spotlight from Clinical Care Options (CCO)